证券日报网讯 2月10日，奇正藏药发布公告称，公司无逾期对外担保、无涉及诉讼对外担保及因担保被 判决败诉而应承担损失的情形。 （文章来源：证券日报） ...

本报讯近日，西藏奇正藏药股份有限公司（以下简称"奇正藏药"）披露公告称，其中国澳门全资子公司 已取得澳门特别行政区政府药物监督管理局核准签发的《中成药注册证明书》，旗下经典藏药催汤颗粒 正式完成澳门注册。这是澳门特别行政区批准的首个藏药品种，标志着奇正藏药国际化战略迈出关键一 步。 据公告，催汤颗粒始载于公元15世纪著名藏医药学家宿喀·娘尼多吉所著的《医学千万舍利》，属于藏 族验方，成分包含藏木香膏、藏木香、悬钩子茎、宽筋藤等道地藏药材，是呼吸系统领域的感冒类用 药。 值得关注的是，此次获批类别为非处方中成药（OTC），意味着该药品可通过中国澳门零售药店等渠道 直接触达消费者。 奇正藏药催汤颗粒获中国澳门批准上市，其重要价值在于以"藏药经典+港澳标准+国际输出"模式，开 创民族医药出海的可复制路径，为公司国际化布局打开重要窗口。公告显示，该事项将有利于公司拓展 境外市场业务。 催汤颗粒在中国澳门完成注册，是奇正藏药近期在呼吸领域的又一重要成果。 回溯一个月前，1月20日，国家药品监督管理局发布《中药保护品种公告（第34号）》，奇正藏药十味 龙胆花胶囊成功获批首家中药二级保护品种，获得长达7年的专属保护期。十味 ...

证券代码：002287 证券简称：奇正藏药 公告编号：2026-004 西藏奇正藏药股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 西藏奇正藏药股份有限公司（以下简称"公司"）第六届董事会第十六次会 议、2026 年第一次临时股东会审议通过了《关于为全资子公司提供担保额度预 计的议案》，同意为全资子公司西藏奇正藏药营销有限公司（以下简称"西藏营 销"）向银行申请综合授信事项提供担保，担保额度不超过人民币 70,000 万元， 自股东会审议通过之日起 12 个月内有效。详见刊登在《证券时报》、巨潮资讯 网（http://www.cninfo.com.cn）上的《第六届董事会第十六次会议决议公告》 （公告编号：2025-104）、《关于为全资子公司提供担保额度预计的公告》（公 告编号：2025-106）以及《2026 年第一次临时股东会决议公告》（公告编号： 2026-001）。 二、担保进展情况 近日，公司与中国民生银行股份有限公司拉萨分行（以下简称"民生银行"） 签订《最高额保证合同》，为西藏 ...

证券代码：002287 证券简称：奇正藏药 公告编号：2026-005 西藏奇正藏药股份有限公司 关于子公司开展票据池业务暨为子公司担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 三、被担保人基本情况 （一）甘肃奇正藏药有限公司 1、被担保人名称：甘肃奇正藏药有限公司 一、担保情况概述 西藏奇正藏药股份有限公司（以下简称"公司"）第六届董事会第十六次会 议、2026 年第一次临时股东会审议通过了《关于公司及子公司开展票据池业务 暨为子公司担保的议案》，同意公司及子公司与国内资信较好的商业银行开展合 计额度不超过人民币 65,000 万元的票据池业务，其中公司为子公司票据池质押 融资担保额度 20,000 万元；票据池业务的开展期限为自股东会审议通过之日起 12 个月。详见刊登在《证券时报》、巨潮资讯网（http://www.cninfo.com.cn） 上的《第六届董事会第十六次会议决议公告》（公告编号：2025-104）、《关于公 司及子公司开展票据池业务暨为子公司担保的公告》（公告编号：2025-107）以 及《2026 年第一次临时股东会 ...

奇正藏药公告称，公司此前同意为全资子公司西藏营销向银行申请综合授信提供不超 7 亿元的担保。近 日，公司与民生银行拉萨分行签订《最高额保证合同》，为西藏营销 4 亿元流动资金贷款提供担保，被 担保主债权发生于 2026 年 2 月 9 日至 2027 年 1 月 7 日，保证方式为不可撤销连带责任保证。截至公告 日，公司及控股子公司担保额度 9 亿元，担保余额 42229.13 万元，无逾期对外担保等情况。 ...

2月4日，奇正藏药（002287）(002287.SZ)披露公告称，其澳门全资子公司已取得澳门特别行政区政府 药物监督管理局核准签发的《中成药注册证明书》，旗下经典藏药催汤颗粒正式完成澳门注册。这是澳 门特别行政区批准的首个藏药品种，标志着奇正藏药国际化战略迈出关键一步。 古方传承显功效OTC属性适配民生需求 澳门是粤港澳大湾区建设"中医药高地"的重要组成部分，更是中医药走向国际的前沿阵地。 奇正藏药催汤颗粒获澳门批准上市，其重要价值在于以"藏药经典+港澳标准+国际输出"模式，开创民 族医药出海的可复制路径，为公司国际化布局打开重要窗口。公告显示，该事项将有利于公司拓展境外 市场业务。 呼吸领域双成果落地多产品战略持续深化 催汤颗粒在澳门完成注册，是奇正藏药近期在呼吸领域的又一重要成果。 回溯一个月前，1月20日，国家药品监督管理局发布《中药保护品种公告(第34号)》，奇正藏药十味龙 胆花胶囊成功获批首家中药二级保护品种，获得长达7年的专属保护期。十味龙胆花胶囊，清热化痰， 止咳平喘，是主治"咳、痰、喘、炎、热"的经典藏药。凭借扎实的循证医学证据，入选《慢性阻塞性肺 疾病中西医结合诊疗指南(2025版)》等多 ...

Core Viewpoint - The recent suspension of procurement qualifications for three major drug products will significantly impact the market strategies and sales expectations of three pharmaceutical companies: China Resources Sanjiu, Jiangsu Zhengda Qingjiang Pharmaceutical, and Tibet Qizheng Tibetan Medicine [1][3][18] Group 1: Impact on Companies - The suspension affects commonly used drugs for cold treatment, osteoarthritis, and external pain relief, disrupting the market plans of the involved companies [3][18] - China Resources Sanjiu's strategy to leverage the sales of Xiao Chai Hu Granules as a key growth driver is now hindered, requiring a reassessment of their market approach [7][18] - Jiangsu Zhengda Qingjiang Pharmaceutical holds a dominant market share of 96.54% for Glucosamine Hydrochloride Tablets, which is crucial for their revenue stability; the suspension will force them to adjust their market strategy [11][12][18] - Tibet Qizheng Tibetan Medicine's core product, Pain Relief Plaster, has been a significant revenue contributor, and the procurement halt will destabilize their market position, necessitating a reconfiguration of their promotional strategies [13][17][18] Group 2: Market Dynamics - Xiao Chai Hu Granules, a key OTC product, generated sales of 242 million yuan in the first three quarters of 2025, reflecting a year-on-year growth of 3.42% [4][5] - Glucosamine Hydrochloride Tablets achieved sales of 372 million yuan in the same period, marking it as a leading product in the osteoarthritis treatment category [10][11] - Pain Relief Plaster has consistently generated over 1 billion yuan in annual sales, with the first three quarters of 2025 alone exceeding 900 million yuan [16][17]

Group 1 - The Chinese medicine (core stocks) sector experienced a significant rise, with notable increases in stock prices for companies such as Zhendong Pharmaceutical (+19.16%) and Shengwugu (+13.86%) [1][2] - The Ministry of Industry and Information Technology and seven other departments recently issued the "Implementation Plan for the High-Quality Development of the Chinese Medicine (Core Stocks) Industry (2026-2030)", aiming to establish a collaborative development system for the entire industry chain by 2030 [2][3] Group 2 - The plan outlines six major actions, including improving raw material quality and supply, enhancing manufacturing capabilities, and promoting the revitalization of the national medicine industry, with 15 specific tasks to be implemented [3] - The initiative aims to cultivate 60 high-standard Chinese medicine raw material production bases and support the establishment of 10 major traditional Chinese medicine varieties, while also promoting innovation in Chinese medicine products [3][4] Group 3 - Companies involved in the planting and processing of Chinese medicinal materials are expected to benefit from the establishment of high-standard production bases and the development of modern seed industries, leading to standardized and large-scale growth opportunities [4] - Firms focusing on innovative research and development in Chinese medicine will gain from the encouragement of AI and big data technologies, which will facilitate the transformation of classic formulas into innovative drugs [4][5] Group 4 - The plan includes the construction of 20 smart factories and 10 green factories, which will enhance production efficiency and product quality through digital transformation [4][5] - Companies like Te Yi Pharmaceutical and Hongri Pharmaceutical are positioned to benefit from the promotion of traditional Chinese medicine products and the digitalization of manufacturing processes, respectively [6]

Group 1 - Shanghai Pharmaceuticals plans to transfer 30% equity stake in China and America Bristol-Myers Squibb for no less than 1.023 billion yuan, aiming to optimize investment structure and achieve asset appreciation [1] - The net profit of the target company for the first three quarters of 2025 was 87.11 million yuan, and the transaction is not expected to have a significant impact, although uncertainties exist regarding the buyer [1] Group 2 - Pianzaihuang's controlling shareholder, Jiulongjiang Group, has received a loan commitment from Industrial and Commercial Bank of China for up to 450 million yuan to support the purchase of additional shares [2] - The controlling shareholder plans to use additional self-funding of 300 million to 500 million yuan for the share acquisition, reflecting confidence in the company's value [2] Group 3 - Qizheng Tibetan Medicine's subsidiary has received a registration certificate for the "Cui Tang Granules" from the Macau government, which is a traditional Chinese medicine for respiratory issues [3] - The approval is expected to help expand the company's presence in overseas markets, although it is not anticipated to have a significant impact on recent performance [3] Group 4 - Zhifei Biological's subsidiary has received approval for clinical trials of a freeze-dried varicella inactivated vaccine, which aims to prevent chickenpox and shingles [4] - The vaccine utilizes self-developed technology and fills a gap in the domestic inactivated vaccine market, but is not expected to have a major short-term impact on performance [4] Group 5 - Innovent Biologics forecasts total product revenue of approximately 11.9 billion yuan for 2025, marking a year-on-year growth of about 45% [5] - The company achieved approximately 3.3 billion yuan in total product revenue in the fourth quarter of 2025, with a year-on-year increase of over 60%, driven by steady growth in 13 oncology products and the release of 3 chronic disease medications [5]

智通财经APP讯，奇正藏药(002287.SZ)公告，公司全资子公司奇正(澳门)国际一人有限公司(简称"奇正 澳门")收到澳门特别行政区政府药物监督管理局核准签发的《中成药注册证明书》，药品名称为：催汤 颗粒〔奇正〕。催汤颗粒功能主治为：清热解表，止咳止痛。用于感冒初起，咳嗽头痛，关节酸痛;防 治流行性感冒。 ...